Catalytic Ring Expansions of Cyclic Alcohols Enabled by Proton-Coupled Electron Transfer
作者:Kuo Zhao、Kenji Yamashita、Joseph E. Carpenter、Trevor C. Sherwood、William R. Ewing、Peter T. W. Cheng、Robert R. Knowles
DOI:10.1021/jacs.9b03973
日期:2019.6.5
the modular ringexpansion of cyclic aliphatic alcohols. In this work, proton-coupled electron transfer activation of an allylic alcohol substrate affords an alkoxy radical intermediate that undergoes subsequent C-C bond cleavage to furnish an enone and a tethered alkyl radical. Recombination of this alkyl radical with the revealed olefin acceptor in turn produces a ring-expanded ketone product. The
我们在这里报告了一种用于环状脂肪醇模块化扩环的催化方法。在这项工作中,烯丙醇底物的质子耦合电子转移活化提供烷氧基自由基中间体,该中间体经历随后的 CC 键断裂以提供烯酮和系链烷基自由基。该烷基与暴露的烯烃受体的重组又产生扩环的酮产物。这种 CC 键形成事件的区域选择性可以通过烯烃底物上的取代基可靠地控制,提供了一种以选择性方式将简单的 N 元环底物转化为 n+1 或 n+2 环加合物的方法。
PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
申请人:GENENTECH, INC.
公开号:US20130079321A1
公开(公告)日:2013-03-28
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Formula I中的吡唑-4-基杂环基-羧酰胺化合物,包括其立体异构体、几何异构体、互变异构体和药学上可接受的盐,其中X为噻唑基、吡啶基、吡啶基或嘧啶基,用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用Formula I化合物进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
申请人:Genentech, Inc.
公开号:US08614206B2
公开(公告)日:2013-12-24
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.